CFGS
CORT icon

Concourse Financial Group Securities’s Corcept Therapeutics CORT Stock Holding History

Concourse Financial Group Securities’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-95
Closed -$1.51K – 2167
2020
Q2 		$2K Hold
95
– – ﹤0.01% 1888
2020
Q1 		$1K Hold
95
– – ﹤0.01% 2011
2019
Q4 		$1K Hold
95
– – ﹤0.01% 1975
2019
Q3 		$1K Buy
+95
New +$1.17K ﹤0.01% 1625
2019
Q1 		– Sell
-506
Closed -$6.29K – 2284
2018
Q4 		$6K Sell
506
-769
-60% -$10.2K ﹤0.01% 1571
2018
Q3 		$18K Buy
+1,275
New +$17.8K 0.01% 885

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concourse Financial Group Securities's CORT Position: Q3 2020 in Review

Concourse Financial Group Securities sold out of Corcept Therapeutics (CORT) in Q3 2020, closing a stake of 95 shares — an estimated $1.51K sold.

Concourse Financial Group Securities first reported a position in CORT in Q3 2018 and held it in 6 quarters. The position peaked at $18K in Q3 2018. 223 funds tracked by Wall St. Rank hold CORT as of Q3 2020.

  • Concourse Financial Group Securities reported no remaining Corcept Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 95 Corcept Therapeutics shares in Q3 2020, an estimated $1.51K.
  • Concourse Financial Group Securities first reported a position in Corcept Therapeutics in Q3 2018 and held it in 6 quarters.
  • Concourse Financial Group Securities's Corcept Therapeutics position peaked at $18K in Q3 2018.
  • 223 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2020.

Based on Concourse Financial Group Securities's 13F filing for Q3 2020, filed 13 Nov 2020.